Research Overview

Our laboratory investigates how chronic inflammation and its resolution control disease progression, with a central focus on bioactive lipids including eicosanoids and pro‑resolving lipid mediators. We aim to define the molecular pathways that control immune balance, tissue repair, and pathological remodeling in cancer and other inflammation-associated disease contexts.

Using a combination of the state-of-the-art inflammation and debris-stimulated cancer models, molecular biology, and other preclinical inflammation-driven models, we study how disrupted resolution programs contribute to cancer, chemical carcinogenesis, cachexia, cardiovascular diseases, and cystic fibrosis. By dissecting these signaling networks, we identify new therapeutic targets and opportunities to restore tissue homeostasis.

Our research is driven by mechanistic rigor, innovation, and exciting close collaborations with Harvard Medical School Profs. Charles Serhan (MGH‑Brigham), Steven Freedman (BIDMC), and Dr. Darry Zeldin (National Institute of Environmental Health Sciences (NIEHS)).

Funding Sources

• NIH R01CA276107-01A2
• NIH R01CA285395-01A1
• NIH RO1 CA170549
• NIH RO1 CA148633
• Credit Union for Kids at Heart
• CJ Buckley Pediatric Brain Tumor Fund
• Thetis Pharmaceuticals
• Tempest Therapeutics